Pulmonary hypertension (PH) is a heterogenous collection of conditions characterized by an increase in blood pressure in the pulmonary vasculature. In the Chan lab, we are using both clinical and lab-based approaches to understanding the progression, mechanisms, and causes of PH.
Using NIH tools and expertise can improve odds of a successful application. In this workshop, we will discuss strategies to make the most of NIH staff and resources to plan and prepare a competitive application and manage the post-submission outcome. Bring any questions you have about the NIH and its grant application and review process.
Where do genes come from? Traditionally, most models for new gene evolution invoke modifications of ancestral genes.
The human microbiome (microbial communities and their gene content) is composed of trillions of cells in multiple ecological niches. Although the lung was initially believed to be sterile in the normal host, recent data indicate that microbial communities are detectable in individuals without lung disease.
Bacterial pathogens have evolved a plethora of different adaptations that confer high-level resistance to certain antibiotics. However, it remains unclear whether the observed adaptations are randomly drawn from a much larger set of possibilities or represent the best of only a few options for obtaining resistance.
Poor electronic medical record (EMR) usability is detrimental to both clinicians and patients. A better EMR would provide concise, context sensitive patient data, but doing so entails the difficult task of knowing which data are relevant.
Mobile technologies such as smartphones and wearable sensors offer unprecedented opportunities to sense and intervene on patient health behaviors in real-time, in real-world contexts, and at enormous scale. This talk will highlight recent and ongoing patient-centered research using mobile sensing and machine learning to predict clinical cancer outcomes such as readmissions and treatment toxicities.